1 / 6

Management choices in breast cancer: maximizing survival with Xeloda

Management choices in breast cancer: maximizing survival with Xeloda. Laura Biganzoli Sandro Pitigliani Medical Oncology Unit Hospital of Prato Prato, Italy. Xeloda: high front-line activity in metastatic breast cancer (MBC). Response rate (%). 60 40 20 0. O’Shaughnessy (n=93) 1.

gabi
Download Presentation

Management choices in breast cancer: maximizing survival with Xeloda

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management choices in breast cancer: maximizing survival with Xeloda Laura Biganzoli Sandro Pitigliani Medical Oncology UnitHospital of PratoPrato, Italy

  2. Xeloda: high front-line activity in metastatic breast cancer (MBC) Response rate (%) 60 40 20 0 O’Shaughnessy(n=93)1 Talbot(n=41)2 Bajetta(n=73)3 Torrecillas(n=62)4 1O’Shaughnessy J et al. Ann Oncol 2001;12:1247–54 2Talbot D et al. Br J Cancer 2002;86:1367–72; 3Bajetta E et al. J Clin Oncol 2005;23:2155–61 4Torrecillas L et al. Breast Cancer Res Treat 2004;88(Suppl. 1):S200 (Abst 5048)

  3. Xeloda: consistently high activity in taxane-pretreated MBC 1Blum JL et al. Eur J Cancer 2001;37(Suppl. 6):S190 (Abst 693)2Blum JL et al. Cancer 2001;92:1759–683Reichardt P et al. Ann Oncol 2003;14:1227–33 4Fumoleau P et al. Eur J Cancer 2004;40:536–425Miller K et al. J Clin Oncol 2005;23:792–9

  4. Xeloda monotherapy in MBC: low incidenceof grade 3/4 adverse events (n=713) Patients (%) 40 30 20 10 0 • Minimal alopecia and myelosuppression • No cumulative toxicity • No treatment-related deaths Hand-foot Diarrhea Fatigue Stomatitis Nausea Dehydration syndrome Blum JL et al. Eur J Cancer 2001;37(Suppl. 6):S190 (Abst 693) Blum JL et al. Cancer 2001;92:1759–68; Reichardt P et al. Ann Oncol 2003;14:1227–33 Fumoleau P et al. Eur J Cancer 2004;40:536–42; Miller K et al. J Clin Oncol 2005;23:792–9

  5. XT (n=255) Taxotere (n=255) Hazard ratio = 0.77 Log-rank p=0.013 11.5 14.5 Addition of Xeloda to Taxotere extends survival Survival probability 1.0 0.8 0.6 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Months 1O’Shaughnessy J et al. J Clin Oncol 2002;20:2812–23

  6. Xeloda: effective and well tolerated • Xeloda monotherapy: high activity and favorable safety in first-line and pretreated MBC1 • Xeloda + Taxotere extends survival in MBC1 • High efficacy and encouraging safety for Xeloda-containing combinations in (neo)adjuvant BC2,3 • Efficacy and safety transfer into clinical practice 1Leonard R et al. Smin Oncol 2004;31(5 Suppl. 10):21–8 2Ro J et al. Breast 2005;14(Suppl. 1):S40 (Abst P89) 3Joensuu H et al. J Clin Oncol 2005;23:57s (Abst 719)

More Related